BCL2 (B-cell CLL/lymphoma 2)

In conclusion, curcumin shows great promise in improving prostate cancer treatment by targeting key cancer pathways and enhancing the effects of existing therapies. While its potential is clear, further clinical studies are needed to refine its use and ensure its effectiveness in real-world applications.

It also discusses recent advances in targeting strategies. The review provides insights for developing effective anti-cancer therapies.

Histological analysis revealed milder dysplasia in the cocoa-treated group compared to controls (p=0.002). Cocoa extract demonstrates potential as a natural chemopreventive agent against skin cancer through antioxidant activity, anti-angiogenesis, and apoptosis modulation pathways.

P1, N=48, Recruiting, Sawa Ito, MD | Not yet recruiting --> Recruiting

Anticancer activity of the racemic complexes C1-C4 against human colorectal adenocarcinoma (HT-29) and human lung cancer (A549) cell lines assessed using MTT assay indicated the IC50 concentrations ranging from 15.39 to 21.86 µM and 17.29 to 24.29 µM for HT-29 and A549 cells, respectively, and the values are comparable to that of the positive control (cisplatin) and also the same assay was performed on human epithelial kidney cells (HEK-293) to determine the selectivity index of the complexes...The complexes demonstrated favorable binding interactions with B-DNA, BSA, cyclooxygenase-2 (COX-2) and B-cell lymphoma-2 (Bcl-2), with high binding affinity values of -8.12, -6.6, -6.25 and -7.53 kcal mol-1, respectively. Simultaneously, binding interactions of the individual enantiomers (R and S) of the respective pairs of each complex towards the target proteins were also examined, but they did not vary greatly among the complexes.

Thus, VALD-3 treatment initiated the ROS/JNK/Bax-mitochondrial apoptosis pathway, leading to caspase-3 activation and GSDME cleavage, thereby executing pyroptosis. These findings suggest that GSDME-dependent pyroptosis is a novel mechanism by which VALD-3 eradicates cancer cells and offer new insights into potential clinical applications for anticancer therapies.

Collectively, network analysis suggests that phytochemicals in Vernolac may exert anticancer effects through multiple cancer-related pathways, including those associated with apoptosis, immune modulation, oxidative stress, inflammation, and cell proliferation. Furthermore, the identified targets and enriched pathways suggest a potential role in modulating drug resistance and treatment response, providing a computational basis for its application as an adjunct to conventional cancer therapies and warranting further investigation in preclinical and clinical settings.

Sonrotoclax demonstrated rapid, durable responses and manageable safety in heavily pretreated patients with R/R MCL, including high-risk subgroups, supporting its further clinical evaluation as an oral therapy for R/R MCL.

Reduced mTOR and p70S6K expression was associated with suppression of cell proliferation and survival signaling. Overall, these findings suggest that MSN-based delivery may enhance the anticancer effects of PTU, highlighting its potential as a therapeutic strategy in cancer research.

P1, N=27, Not yet recruiting, Luminary Therapeutics

It is characterized by nuclear and cytoplasmic beta catenin expression indicating activation of Wnt/beta-catenin signaling pathway. We present a case of cribriform morular thyroid carcinoma with nodal recurrence, initially misdiagnosed as tall cell PTC highlighting its diagnostic challenges and clinical relevance of accurate diagnosis.

Overall, our findings indicate that ICP27 differentially modulates apoptotic signaling depending on the cellular context, enhancing pro-apoptotic features in epithelial cells while limiting intrinsic pathway activation in neuron-like cells. This dual behavior underscores HSV-1 adaptability across microenvironments, with implications for viral pathogenesis and therapeutic targeting.